mProX™ Human PRKACA Stable Cell Line

Cui, Can. et al. "Sesquiterpenoids from Alpinia oxyphylla with GLP-1 Stimulative Effects through Ca2+/CaMKII and PKA Pathways and Multiple-Enzyme Inhibition." Journal of agricultural and food chemistry, 2023.
Researchers have identified six novel sesquiterpenoids (1-6) along with a pair of enantiomers (7a and 7b), as well as six previously known compounds (8-13) in Alpinia oxyphylla fruit extracts. The chemical structures of the new compounds were established through comprehensive spectroscopic analysis and ECD calculations. Significantly, the stereochemistry of 7a and 7b has been documented for the first time. These compounds demonstrated substantial GLP-1 stimulation in NCI-H716 cells, with stimulation ratios ranging from 90.4% to 668.9% at 50 μM. Further investigations revealed that compound 6 primarily enhanced GLP-1 secretion by regulating proglucagon transcription and processing, while compound 13 increased prkaca levels to exert its effects. Intriguingly, both compounds 6 and 13 were closely associated with Ca2+/CaMKII and PKA pathways in stimulating GLP-1 but had no relevance to TGR5 and GPR119 receptors. Additionally, most compounds exhibited inhibitory activity against α-glucosidase and PTP1B at concentrations of 100 and 200 μM, with no activity against GPa. Compounds 3, 9, 11, and 13 effectively suppressed α-glucosidase, displaying IC50 values comparable to acarbose (IC50 = 212.0 μM). This study underscores the rich diversity of sesquiterpenoids in A. oxyphylla with multifaceted biological activities.
Cui, Can. et al. "Sesquiterpenoids from Alpinia oxyphylla with GLP-1 Stimulative Effects through Ca2+/CaMKII and PKA Pathways and Multiple-Enzyme Inhibition." Journal of agricultural and food chemistry, 2023.
Pubmed: 37871265   DOI: 10.1021/acs.jafc.3c06093

Liu, Muyin. et al. "Integrative proteomic analysis reveals the cytoskeleton regulation and mitophagy difference between ischemic cardiomyopathy and dilated cardiomyopathy." Molecular & cellular proteomics : MCP, 2023.
Ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) represent the primary causes of end-stage heart failure. However, there is a significant lack of comprehensive understanding regarding the global proteome and phosphoproteome dynamics in ICM and DCM, hindering a deep grasp of their fundamental biological characteristics and signaling mechanisms. Through extensive high-throughput quantification proteomics and phosphoproteomics analyses of clinical heart tissues afflicted with ICM or DCM, researchers gained comprehensive molecular insights into the pathogenesis of heart failure in both conditions. This investigation unveiled distinct protein and phosphorylation expression patterns between heart failure and normal heart tissues, emphasizing the unique features of ICM and DCM. Notably, the study highlighted the activation of the PRKACA-GSK3β signaling pathway in ICM, impacting microtubule network remodeling and actin filament regulation. Additionally, DCM exhibited pronounced mitochondrial energy supply impairment compared to ICM, leading to ROCK1-vimentin signaling pathway activation and enhanced mitophagy. This research not only elucidates key distinctions between ICM and DCM but also sheds light on the differing underlying mechanisms, offering valuable insights for potential therapeutic targets in the treatment of various heart failure types.
Liu, Muyin. et al. "Integrative proteomic analysis reveals the cytoskeleton regulation and mitophagy difference between ischemic cardiomyopathy and dilated cardiomyopathy." Molecular & cellular proteomics : MCP, 2023.
Pubmed: 37852321   DOI: 10.1016/j.mcpro.2023.100667